MA54696A - Inhibiteurs imidazo [1,2-b]pyridazine il-17 a - Google Patents
Inhibiteurs imidazo [1,2-b]pyridazine il-17 aInfo
- Publication number
- MA54696A MA54696A MA054696A MA54696A MA54696A MA 54696 A MA54696 A MA 54696A MA 054696 A MA054696 A MA 054696A MA 54696 A MA54696 A MA 54696A MA 54696 A MA54696 A MA 54696A
- Authority
- MA
- Morocco
- Prior art keywords
- imidazo
- pyridazine
- inhibitors
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title 1
- 108050003558 Interleukin-17 Proteins 0.000 title 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789247P | 2019-01-07 | 2019-01-07 | |
| US201962842770P | 2019-05-03 | 2019-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54696A true MA54696A (fr) | 2022-04-13 |
Family
ID=69423406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054696A MA54696A (fr) | 2019-01-07 | 2020-01-03 | Inhibiteurs imidazo [1,2-b]pyridazine il-17 a |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12252491B2 (fr) |
| EP (1) | EP3908585B1 (fr) |
| JP (1) | JP7291226B2 (fr) |
| KR (1) | KR102600451B1 (fr) |
| CN (1) | CN113286795B (fr) |
| AU (1) | AU2020207196B2 (fr) |
| BR (1) | BR112021011095B1 (fr) |
| CA (1) | CA3125788C (fr) |
| CL (1) | CL2021001720A1 (fr) |
| CO (1) | CO2021008776A2 (fr) |
| CR (1) | CR20210357A (fr) |
| DO (1) | DOP2021000132A (fr) |
| EC (1) | ECSP21050201A (fr) |
| ES (1) | ES2977743T3 (fr) |
| IL (1) | IL284228B2 (fr) |
| JO (1) | JOP20210179A1 (fr) |
| MA (1) | MA54696A (fr) |
| MX (1) | MX2021008176A (fr) |
| NZ (1) | NZ777806A (fr) |
| PE (1) | PE20212304A1 (fr) |
| PH (1) | PH12021551632A1 (fr) |
| SA (1) | SA521422452B1 (fr) |
| SG (1) | SG11202105776WA (fr) |
| TW (2) | TWI752400B (fr) |
| WO (1) | WO2020146194A1 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006421A (es) | 2018-12-19 | 2021-08-16 | Leo Pharma As | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). |
| GB201909190D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| JP7664947B2 (ja) | 2020-04-30 | 2025-04-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Il-17の調節因子としてのイミダゾリダジン |
| MX2022015554A (es) | 2020-06-12 | 2023-01-30 | Leo Pharma As | Moduladores de molecula peque?a de interleucina 17 (il-17). |
| WO2021255086A1 (fr) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Modulateurs à petites molécules d'il-17 |
| US20230227435A1 (en) | 2020-06-18 | 2023-07-20 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2021255085A1 (fr) | 2020-06-18 | 2021-12-23 | Leo Pharma A/S | Modulateurs à petites molécules d'il-17 |
| EP3943495A1 (fr) | 2020-07-24 | 2022-01-26 | Leo Pharma A/S | Modulateurs de petites molécules d'il-17 |
| CN113999234B (zh) * | 2020-07-28 | 2023-03-07 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2022096411A1 (fr) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dérivés de dicyclopropylméthyle en tant que modulateurs d'il-17 |
| WO2022096412A1 (fr) | 2020-11-09 | 2022-05-12 | UCB Biopharma SRL | Dérivés de dicyclopropylméthyle en tant que modulateurs d'il-17 |
| US20240140951A1 (en) | 2020-12-14 | 2024-05-02 | UCB Biopharma SRL | Imidazopyridazine derivatives as il-17 modulators |
| AR126255A1 (es) | 2021-07-01 | 2023-10-04 | UCB Biopharma SRL | Derivados de imidazotriazina como moduladores de il-17 |
| WO2023025783A1 (fr) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Modulateurs à petites molécules d'il-17 |
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| CA3233622A1 (fr) * | 2021-09-27 | 2023-03-30 | Janssen Pharmaceutica Nv | Composes benzimidazoles et azabenzimidazoles inhibiteurs de l'il-17 |
| AU2022348938A1 (en) * | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| WO2023078319A1 (fr) * | 2021-11-04 | 2023-05-11 | 海思科医药集团股份有限公司 | Composé hétérocyclique apte à inhiber l'il-17 a et utilisation d'un composé hétérocyclique |
| WO2023111181A1 (fr) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Modulateurs à petites molécules d'il-17 |
| EP4486737A1 (fr) | 2022-03-04 | 2025-01-08 | LEO Pharma A/S | Modulateurs à petites molécules d'il-17 |
| CN114736104B (zh) * | 2022-04-20 | 2024-04-19 | 上海恩氟佳科技有限公司 | 一种二氟乙醛缩半乙醇的合成方法 |
| KR20250023378A (ko) * | 2022-05-19 | 2025-02-18 | 다이스 알파, 인크. | 락탐 치환된 이미다조피리다진 il-17a 조정제 및 그의 용도 |
| GB202210731D0 (en) | 2022-07-22 | 2022-09-07 | UCB Biopharma SRL | Therapeutic agents |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| WO2024138286A1 (fr) * | 2022-12-26 | 2024-07-04 | Usynova Pharmaceuticals, Ltd. | Modulateurs d'il-17a |
| AU2024213283A1 (en) * | 2023-01-30 | 2025-08-14 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| KR20250145089A (ko) * | 2023-02-13 | 2025-10-13 | 다이스 알파, 인크. | 이미다조트리아진 il-17a 조정제 및 그의 용도 |
| EP4688156A1 (fr) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Composés inhibiteurs d'il-17 de type imidazopyridazine contenant du lactame |
| WO2024215597A1 (fr) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Composés 6-imidazopyridazines substitués modulateurs de l'il-17a et leurs utilisations |
| AU2024363335A1 (en) | 2023-10-19 | 2026-05-07 | Hitgen Inc. | Immunomodulators |
| WO2025133234A1 (fr) | 2023-12-22 | 2025-06-26 | Draupnir Bio Aps | Liants de sortiline et composés bifonctionnels associés |
| WO2025175249A1 (fr) | 2024-02-14 | 2025-08-21 | Olema Pharmaceuticals, Inc. | Modulateurs du récepteur des oestrogènes et leurs utilisations |
| WO2025247285A1 (fr) * | 2024-05-28 | 2025-12-04 | 西藏海思科制药有限公司 | Procédé de préparation d'un composé hétérocyclique apte à inhiber l'il-17a, et son utilisation |
| WO2026039171A1 (fr) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Inhibiteurs de l'il-17a |
| WO2026039170A1 (fr) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Inhibiteurs de l'il-17a |
| WO2026039167A1 (fr) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Inhibiteurs de l'il-17a |
| WO2026039168A1 (fr) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Inhibiteurs de l'il-17a |
| WO2026039172A1 (fr) | 2024-08-12 | 2026-02-19 | Dice Alpha, Inc. | Inhibiteurs de l'il-17a |
| WO2026073936A1 (fr) * | 2024-10-02 | 2026-04-09 | UCB Biopharma SRL | Dérivés d'imidazotriazine utilisés en tant que modulateurs d'il-17 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9702213D0 (en) * | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| WO2007104696A1 (fr) * | 2006-03-15 | 2007-09-20 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Agents antimalariaux de structure polyaromatique |
| EP2441768A1 (fr) * | 2006-11-13 | 2012-04-18 | Eli Lilly & Co. | Thiénopyrimidinones destinées au traitement de troubles inflammatoires et de cancers |
| EP2809660B1 (fr) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Composés macrocycliques pour une modulation d'il-17 |
| EP2892899B1 (fr) * | 2012-09-06 | 2018-03-21 | Bristol-Myers Squibb Company | Inhibiteurs de jak3 de type imidazopyridazine et leur utilisation pour le traitement de maladies inflammatoires et auto-immunes |
| WO2014066726A2 (fr) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Composés pour la modulation d'il-17 |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| EP2958920A1 (fr) | 2013-02-20 | 2015-12-30 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-b]pyridazines substituées comme inhibiteurs de mknk1 |
| ES2702126T3 (es) * | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2016037171A1 (fr) | 2014-09-05 | 2016-03-10 | The Cleveland Clinic Foundation | Flavonoïdes inhibiteurs d'il-17a |
| BR112018005861B1 (pt) | 2015-09-23 | 2022-11-22 | Reata Pharmaceuticals, Inc | Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos |
| KR102782807B1 (ko) * | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| GB201709456D0 (en) | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| CN111601799B (zh) | 2018-01-15 | 2023-06-09 | Ucb生物制药有限责任公司 | 作为Il-17调节剂的稠合咪唑衍生物 |
| WO2019223718A1 (fr) | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | Immunomodulateur |
| MX2021006421A (es) | 2018-12-19 | 2021-08-16 | Leo Pharma As | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). |
| CN113874080B (zh) | 2019-02-06 | 2024-09-27 | 戴斯阿尔法公司 | Il-17a调节剂及其用途 |
-
2020
- 2020-01-02 TW TW109100073A patent/TWI752400B/zh not_active IP Right Cessation
- 2020-01-02 TW TW111100669A patent/TW202214648A/zh unknown
- 2020-01-03 SG SG11202105776WA patent/SG11202105776WA/en unknown
- 2020-01-03 BR BR112021011095-0A patent/BR112021011095B1/pt active IP Right Grant
- 2020-01-03 MX MX2021008176A patent/MX2021008176A/es unknown
- 2020-01-03 MA MA054696A patent/MA54696A/fr unknown
- 2020-01-03 NZ NZ777806A patent/NZ777806A/en unknown
- 2020-01-03 CA CA3125788A patent/CA3125788C/fr active Active
- 2020-01-03 ES ES20703322T patent/ES2977743T3/es active Active
- 2020-01-03 KR KR1020217020765A patent/KR102600451B1/ko active Active
- 2020-01-03 EP EP20703322.6A patent/EP3908585B1/fr active Active
- 2020-01-03 JP JP2021539549A patent/JP7291226B2/ja active Active
- 2020-01-03 US US17/419,997 patent/US12252491B2/en active Active
- 2020-01-03 CN CN202080008309.9A patent/CN113286795B/zh active Active
- 2020-01-03 WO PCT/US2020/012115 patent/WO2020146194A1/fr not_active Ceased
- 2020-01-03 IL IL284228A patent/IL284228B2/en unknown
- 2020-01-03 PH PH1/2021/551632A patent/PH12021551632A1/en unknown
- 2020-01-03 AU AU2020207196A patent/AU2020207196B2/en active Active
- 2020-01-03 PE PE2021001117A patent/PE20212304A1/es unknown
- 2020-01-03 CR CR20210357A patent/CR20210357A/es unknown
-
2021
- 2021-06-22 DO DO2021000132A patent/DOP2021000132A/es unknown
- 2021-06-25 CL CL2021001720A patent/CL2021001720A1/es unknown
- 2021-07-01 CO CONC2021/0008776A patent/CO2021008776A2/es unknown
- 2021-07-01 SA SA521422452A patent/SA521422452B1/ar unknown
- 2021-07-07 EC ECSENADI202150201A patent/ECSP21050201A/es unknown
- 2021-07-07 JO JOP/2021/0179A patent/JOP20210179A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284228A (en) | imidazo[1,2-b]pyridazine il-17a inhibitors | |
| FIC20253011I1 (fi) | Vantsakaftori tai sen farmaseuttisesti hyväksyttävä suola, edullisesti sen kalsiumsuola | |
| DK3762385T3 (da) | Substituerede 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-oner | |
| EP4045442A4 (fr) | Dépalettiseur robotisé assisté par vision | |
| DK3921009T3 (da) | Urinkateter | |
| DK3583105T3 (da) | Pyrrol[1,2-b]pyridazinderivater | |
| DK3959211T3 (da) | 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser | |
| EP3826646A4 (fr) | Profilage microbiomique urinaire | |
| LT3820872T (lt) | Pirolo[1,2-b]piridazino dariniai | |
| IL290445A (en) | [1,2,4]triazolo[1,5-c]quinazolin-5-amines | |
| DK3840832T3 (da) | Imidazo[1,2-b]pyridaziner som trk-inhibitorer | |
| EP4006031A4 (fr) | Inhibiteur de jak2 sélectif de dihydro-pyrrolo-pyrimidine | |
| EP4192030C0 (fr) | Écouteur | |
| DK3821934T3 (da) | Intelligent urinvejskateter | |
| PT3956322T (pt) | Inibidor seletivo de cinase jak1 | |
| MA54960A (fr) | Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine | |
| IL280122A (en) | Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors | |
| EP3936535A4 (fr) | Ionomère multidimensionnel | |
| PL3726603T3 (pl) | Sposób wytwarzania akumulatora | |
| SG11202102363PA (en) | FURO[3,4-b]PYRROLE-CONTAINING BTK INHIBITOR | |
| EP4408967A4 (fr) | Répliques de brandy | |
| HK40053300A (en) | Imidazo[1,2-b]pyridazine il-17a inhibitors | |
| EP3805214A4 (fr) | Inhibiteur sélectif de jak3 | |
| HK40069065A (zh) | Jak1选择性激酶抑制剂 | |
| ES1229045Y (es) | Base rodante autoportante portacargas |